Using the transgenic EF1α- GsαR201C mouse model of FD [16] and a murine analog of denosumab anti-mouse RANKL antibody (anti-mRANKL Ab), we recently demonstrated that the beneficial effect of RANKL inhibition in FD is underlaid by critical changes in the histopathology of the disease [17]. Here, TNFSF11 is linked to Fabry disease.